The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kovalenko Yu.A.

Federal state budgetary institution «A.A. Vishnevsky Institute of Surgery», Russian Ministry of Health (director: B.A. Kubyshkin, member of Russian Academy of Sciences]

Zharikov Yu.O.

Institute of Surgery named after A.V. Vishnevskiy, Moscow

Portal cholangiocarcinoma: epidemiology, staging principles and aspects of tumor biology

Authors:

Kovalenko Yu.A., Zharikov Yu.O.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2017;(11): 85‑91

DOI: 10.17116/hirurgia20171185-91

Read: 5909 times

Download PDF (RU)
Contact the author
Table of contents

PORTAL CHOLANGIOCARCINOMA: EPIDEMIOLOGY, STAGING PRINCIPLES AND ASPECTS OF TUMOR BIOLOGY
PORTAL CHOLANGIOCARCINOMA: EPIDEMIOLOGY, STAGING PRINCIPLES AND ASPECTS OF TUMOR BIOLOGY

To cite this article:

Kovalenko YuA, Zharikov YuO. Portal cholangiocarcinoma: epidemiology, staging principles and aspects of tumor biology. Pirogov Russian Journal of Surgery. 2017;(11):85‑91. (In Russ.)
https://doi.org/10.17116/hirurgia20171185-91

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Difficult intu­bation risk asse­ssment in bariatric surgery. Russian Journal of Anesthesiology and Reanimatology. 2025;(1):62-68
Analysis of dyna­mics and fore­cast of morbidity of diseases of the urogenital system in the child popu­lation living in the Repu­blic of Sakha (Yakutia). Russian Journal of Preventive Medi­cine. 2025;(3):60-66
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
The phenomenon of tumor budding in gastric cancer. Russian Journal of Archive of Pathology. 2025;(2):79-87
Diagnostic and prognostic pote­ntial of modern biomarkers in community-acquired pneumonia in children. Russian Journal of Preventive Medi­cine. 2025;(4):130-135
Pathogenetic aspe­cts of autoantibody formation to central nervous system stru­ctures in patients with ence­phalitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):53-58
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
Hema­tological indi­cators of the systemic inflammatory response in the prognosis of lumi­nal HER2-negative breast cancer patients unde­rgoing surgery followed by adju­vant therapy. P.A. Herzen Journal of Onco­logy. 2025;(3):31-38
Abstract:

Keywords:

hilar cholangiocarcinoma
molecular biology of tumor
prognosis

Authors:

Kovalenko Yu.A.

Federal state budgetary institution «A.A. Vishnevsky Institute of Surgery», Russian Ministry of Health (director: B.A. Kubyshkin, member of Russian Academy of Sciences]

Zharikov Yu.O.

Institute of Surgery named after A.V. Vishnevskiy, Moscow

Close metadata

References:

  1. Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98(12):873-875.
  2. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512-522. https://doi.org/10.1038/nrgastro.2011.131
  3. Ebata T, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M, Kokudo N, Miyagawa S, Takada T, Nagino M. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg. 2014;101(2):79-88. https://doi.org/10.1002/bjs.9379
  4. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241-256.
  5. Altemeier WA, Gall EA, Zinninger MM, Hoxworth PI. Sclerosing carcinoma of the major intrahepatic bile ducts. AMA Arch Surg. 1957;75(3):450-460.
  6. de Jong MC, Hong SM, Augustine MM, Goggins MG, Wolfgang CL, Hirose K, Schulick RD, Choti MA, Anders RA, Pawlik TM. Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch Surg. 2011;146(6):697-703. https://doi.org/10.1001/archsurg.2011.122
  7. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 g. Pod red. Kaprina A.D., Starinskogo V.V., Petrovoi G.V. Mosk. nauch.-issled. onkol. in-t im. P.A. Gertsena. M.: MNIOI im. P.A. Gertsena; 2016. (In Russ.)
  8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2010.
  9. Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D’Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221(6):1041-1049. https://doi.org/10.1016/j.jamcollsurg.2015.09.005
  10. Bagante F, Tran T, Spolverato G, Ruzzenente A, Buttner S, Ethun CG, Groot Koerkamp B, Conci S, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Vitiello G, IJzermans JN, Maithel SK, Poultsides G, Guglielmi A, Pawlik TM. Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. J Am Coll Surg. 2016;222(5):750-759. https://doi.org/10.1016/j.jamcollsurg.2016.02.012
  11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. https://doi.org/10.3322/caac.21254
  12. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173-184. https://doi.org/10.1002/hep.24351
  13. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3(1):18-34. https://doi.org/10.3978/j.issn.2304-3881.2014.02.05
  14. Klinicheskie rekomendatsii po diagnostike i lecheniyu bol’nykh rakom pecheni i vnepechenochnykh zhelchnykh protokov. Pod red. Assotsiatsii onkologov Rossii. M. 2014. (In Russ.)
  15. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours, WHO classification of tumours of the digestive system. Vol. 3, 4th ed. Lyon. 2010.
  16. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE,Vauthey JN. Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts. Arch Pathol Lab Med. 2010;134(4):8-13. https://doi.org/10.1043/1543-2165-134.4.e8
  17. Castellano-Megías VM, Ibarrola-de Andrés C, Colina-Ruizdelgado F. Pathological aspects of so called «hilar cholangiocarcinoma». World J Gastrointest Oncol. 2013;5(7):159-170. https://doi.org/10.4251/wjgo.v5.i7.159
  18. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara; 2000.
  19. Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, Miyachi M, Uesaka K. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227(3):405-411.
  20. Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, Miyachi M, Uesaka K. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227(3):405-411.
  21. Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, DeMatteo RP, D’Angelica M, Koea J, Blumgart LH. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241(5):703-712; discussion 712-714.
  22. Miyazaki M, Ohtsuka M, Miyakawa S, Nagino M, Yamamoto M, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci. 2015;22(3):181-196. https://doi.org/10.1002/jhbp.211
  23. Klinicheskie rekomendatsii po lecheniyu bol'nykh rakom vnepechenochnykh zhelchnykh protokov. Proekt// Pod redak. Bazina I.S., Bredera V.V., Dolgushina B.I. i dr. Moskva. – 2014. (In Russ.)
  24. Bhuiya MR, Nimura Y, Kamiya J, Kondo S, Fukata S, et al. Clinicopathologic studies on perineural invasion of bile duct carcinoma. Ann Surg. 1992;215(4):344-349.
  25. Yamaguchi K, Chijiiwa K, Saiki S, Shimizu S, Takashima M, Tanaka M. Carcinoma of the extrahepatic bile duct: mode of spread and its prognostic implications. Hepatogastroenterology. 1997;44(17):1256-1261.
  26. Ramacciato G, Nigri G, Bellagamba R, Petrucciani N, Ravaioli M, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg. 2010;76(11): 1260-1268.
  27. Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, Hruban RH, Anders RA. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery. 2009;146(2):250-257. https://doi.org/10.1016/j.surg.2009.02.023
  28. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 2005;7(2):121-127. https://doi.org/10.1016/j.ccr.2005.01.017
  29. Lymboussaki A, Partanen TA, Olofsson B, Thomas-Crusells J, Fletcher CD, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol. 1998;153(2):395-403. https://doi.org/10.1016/S0002-9440(10)65583-6
  30. Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, et al. Tumor- associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15(3):791-799. https://doi.org/10.1245/s10434-007-9774-0
  31. Christiansen A, Detmar M. Lymphangiogenesis and cancer. Genes Cancer. 2011;2(12):1146-1158. https://doi.org/10.1177/1947601911423028
  32. Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P, et al. Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. Am J Gastroenterol. 2010;105(5):1123-1132. https://doi.org/10.1038/ajg.2009.674
  33. Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer. 1999;85(4):769-778.
  34. Tojima Y, Nagino M, Ebata T, Uesaka K, Kamiya J, Nimura Y. Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with other wise node-negative hilar cholangiocarcinoma. Ann Surg. 2003;237(2):201-207. https://doi.org/10.1097/01.SLA.0000048446.18118.FC
  35. Taniguchi K, Iida T, Hori T, Yagi S, Imai H, et al. Impact of lymph node micrometastasis in hilar bile duct carcinoma patients. World J Gastroenterol. 2006;12(16):2549-2555.
  36. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-2179. https://doi.org/10.1016/S0140-6736(13)61903-0
  37. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558. https://doi.org/10.1126/science.1235122
  38. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-890. https://doi.org/10.1016/j.cell.2009.11.007
  39. Nitta T, Mitsuhashi T, Hatanaka Y, Miyamoto M, Oba K, et al. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray. Br J Cancer. 2014;111(7):1363-1372. https://doi.org/10.1038/bjc.2014.415
  40. Sato Y, Harada K, Itatsu K, Ikeda H, Kakuda Y, et al. Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol. 2010;177(1):141-152. https://doi.org/10.2353/ajpath.2010.090747
  41. Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech. 2013;6(2):281-292. https://doi.org/10.1242/dmm.010561
  42. Dong LW, Hou YJ, Tan YX, Tang L, Pan YF, et al. Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy. 2011;7(10):1222-1229. https://doi.org/10.4161/auto.7.10.16610
  43. Zhou WH, Tang F, Xu J, Wu X, Yang SB, et al. Low expression of Beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer. Autophagy. 2012;8(3):389-400. https://doi.org/10.4161/auto.18641
  44. Wang TT, Cao QH, Chen MY, Xia Q, Fan XJ, et al. Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma. PLoS One. 2013;8(11):80317. https://doi.org/10.1371/journal.pone.0080317
  45. Paolicchi E, Pacetti P, Giovannetti E, Mambrini A, Orlandi M, et al. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncol Lett. 2013;6(5):1487-1491.
  46. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol. 2002;17(10):1056-1063.
  47. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169(3):877-888.
  48. Mancino A, Mancino MG, Glaser SS, Alpini G, Bolognese A, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 2009;41(2):156-163. https://doi.org/10.1016/j.dld.2008.02.015
  49. Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2007;33(8):1025-1029. https://doi.org/10.1016/j.ejso.2007.02.020
  50. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, et al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol. 2008;21(3):256-264. https://doi.org/10.1038/modpathol.3800985
  51. Morell CM, Fabris L, Strazzabosco M. Vascular biology of the biliary epithelium. J Gastroenterol Hepatol. 2013;28(suppl 1):26-32. https://doi.org/10.1111/jgh.12022
  52. Baldwin ME, Stacker SA, Achen MG. Molecular control of lymphangiogenesis. Bioessays. 2002;24(11):1030-1040. https://doi.org/10.1002/bies.10173
  53. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2(8):573-583. https://doi.org/10.1038/nrc863
  54. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 2002;16(9):922-934. https://doi.org/10.1096/fj.01-0945rev
  55. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006;5(15):1597-1601. https://doi.org/10.4161/cc.5.15.3112
  56. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332-337. https://doi.org/10.1038/nature03096
  57. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003;107(1):1-10. https://doi.org/10.1002/ijc.11335
  58. Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol. 2001;11(2):97-104. https://doi.org/10.1006/scbi.2000.0361
  59. Shinohara ET, Maity A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Curr Mol Med. 2009;9(9):1034-1045.
  60. de Visser KE, Jonkers J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr Pharm Des. 2009;15(16):1844-1853.
  61. Onimaru M, Yonemitsu Y. Angiogenic and lymphangiogenic cascades in the tumor microenvironment. Front Biosci (Schol Ed). 2011;3:216-225.
  62. Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316(17):2713-2722. https://doi.org/10.1016/j.yexcr.2010.04.032
  63. Rojas A, Figueroa H., Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis. 2010;31(3):334-341. https://doi.org/10.1093/carcin/bgp322
  64. Leyva-Illades D, McMillin M, Quinn M, Demorrow S. Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Transl Gastrointest Cancer. 2012;1(1):71-80.
  65. Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol. 2009;7(11 suppl):68-78. https://doi.org/10.1016/j.cgh.2009.08.023
  66. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep. 2009;21(4):957-969.
  67. Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(9):2555-2564. https://doi.org/10.1245/s10434-009-0568-4
  68. Sica A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol. 2010;32(3):153-158.
  69. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2mononuclear phagocytes. Trends Immunol. 2002;23(11): 549-555.
  70. Valls C, Ruiz S, Martinez L, Leiva D. Radiological diagnosis and staging of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013;5(7):115-126. https://doi.org/10.4251/wjgo.v5.i7.115
  71. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140(2): 170-178.
  72. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215(1):31-38.
  73. Suarez-Munoz MA, Fernandez-Aguilar JL, Sanchez-Perez B, Perez-Daga JA, Garcia-Albiach B, et al. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013;5(7):132-138. https://doi.org/10.4251/wjgo.v5.i7.132
  74. Paul A, Kaiser GM, Molmenti EP, Schroeder T, Vernadakis S, Oezcelik A, et al. Klatskin tumors and the accuracy of the Bismuth-Corlette classification. Am Surg. 2011;77(12):1695-1699.
  75. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg. 1998;228(3):385-394.
  76. Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011;53(4):1363-1371. https://doi.org/10.1002/hep.24227
  77. Osnes M, Serck-Hanssen A, Myren J. Endoscopic retrograde brush cytology (ERBC) of the biliary and pancreatic ducts. Scand J Gastroenterol. 1975;10(8):829-831.
  78. Jailwala J, Fogel EL, Sherman S, Gottlieb K, Flueckiger J, et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc. 2000;51(4 Pt 1):383-390.
  79. Macken E, Drijkoningen M, Van Aken E, Van Steenbergen W. Brush cytology of ductal strictures during ERCP. Acta Gastroenterol Belg. 2000;63(3):254-259.
  80. Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg. 2012;147(1):26-34. https://doi.org/10.1001/archsurg.2011.771
  81. Pugliese V, Conio M, Nicolò G, Saccomanno S, Gatteschi B. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc. 1995;42(6):520-526.
  82. Weber A, von Weyhern C, Fend F, Schneider J, Neu B, et al. Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. World J Gastroenterol. 2008;14(7):1097-1101.
  83. Zeller T, Rastan A, Sixt S, Schwarzwälder U, Schwarz T, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48(8):1573-1578. https://doi.org/10.1016/j.jacc.2006.07.031
  84. Schwartz JJ, Thiesset HF, Clayton F, Adler DG, Hutson WR, Carlisle JG. Using the modern Silverhawk atherectomy catheter to characterize biliary structures that appear malignant: review of initial experience. HPB (Oxford). 2011;13(11):823-829. https://doi.org/10.1111/j.1477-2574.2011.00376.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.